Safety, ethics and regulations
This invaluable resource discusses the saftey, ethics, and regulations of developing stem cell clinical applications. Each chapter is contributed by a preeminent scientist in the field and covers such topics as clinical safety of stem cell gene therapy, the patentability of hESC technologies, intern...
Saved in:
| Other Authors | , |
|---|---|
| Format | Electronic eBook |
| Language | English |
| Published |
Springer Verlag
2017.
|
| Series | Stem cells in clinical applications.
|
| Subjects | |
| Online Access | Full text |
| ISBN | 9783319591650 9783319591643 |
| Physical Description | 1 online resource |
Cover
Table of Contents:
- Preface; About the Editors; Contents; Contributors; Part I: Safety; Chapter 1: The Safety of Allogeneic Stem Cell Transplantation; 1.1 Introduction; 1.2 Stem Cell Sources; 1.2.1 Bone Marrow; 1.2.2 Peripheral Blood Stem Cells; 1.2.3 Umbilical Cord Blood; 1.3 Donor Selection and Testing; 1.3.1 HLA Restrictions; 1.3.2 Related Donor; 1.3.3 Unrelated Donor; 1.3.4 Cord Blood; 1.4 Reported Microbiological Transmissions; 1.4.1 Transmission of Human Immunodeficiency Virus Type 1 (HIV-1); 1.4.1.1 Prevention of HIV Transmission by a Viremic Donor; 1.4.2 Transmission of Hepatitis B Virus (HBV).
- 1.4.2.1 How to Proceed with Anti-HBc-Positive Donors?1.4.2.2 Prevention of HBV Infection in Case of HBV Viremic Donors; 1.4.3 Transmission of Hepatitis C Virus (HCV); 1.4.3.1 Prevention of HCV Transmission; 1.4.4 Transmission of HTLV-I + II; 1.4.5 Cytomegalic Virus (CMV) in CMV-Negative Recipients; 1.4.6 Possible Risks from Donors with Epstein-Barr Virus (EBV); 1.4.7 Transmission of Treponema pallidum; 1.4.8 Commensal Bacteria; 1.4.9 Other Pathogens; 1.5 Transfusion-Related Complications; 1.5.1 Transfusion-Related Acute Lung Injury (TRALI); 1.5.2 Hemolytic Transfusion Reaction (HTR).
- 1.6 Risk of Transmission of Donor-Derived Noninfectious Diseases1.6.1 Possible Long-Time Effects; 1.6.2 Donor-Derived Malignancies; 1.7 Conclusion; References; Chapter 2: Induced Pluripotent Stem Cell Therapy and Safety Concerns in Age-Related Chronic Neurodegenerative Diseases; 2.1 Overview of Age-Related Chronic Neurodegenerative Diseases; 2.1.1 Alzheimer's Disease; 2.1.2 Parkinson's Disease; 2.2 Induced Pluripotent Stem Cells Technology; 2.2.1 Reprogramming Methods; 2.2.1.1 Viral Vector-Based Methods; 2.2.1.2 Naked DNA-Based Methods; 2.2.1.3 Non-DNA-Based Methods; 2.3 Applications of iPSCs.
- 2.3.1 Disease Modeling2.3.2 Drug Screening and Testing; 2.3.3 Cell Replacement Therapy; 2.4 Future Directions: Challenges and Advancements; 2.4.1 Limitations in iPSC Generation and Potential Solutions; 2.4.1.1 Integration into Genome; 2.4.1.2 Epigenetic Memory; 2.4.1.3 Differentiation and Purity; 2.4.1.4 Control Groups for Research; 2.4.2 Safety Concerns for Clinical Grade iPSCs; 2.4.2.1 Tumorigenicity, Immunogenicity, and Genomic Instability; 2.4.2.2 Biobanking; 2.4.2.3 Clearance of Animal Products; 2.4.3 Recent Biological and Biotechnological Advancements.
- 2.4.3.1 Alternative Strategies for Reprogramming2.4.3.2 Three-Dimensional (3D) and Organoid Cultures; 2.4.3.3 Biotechnological Strategies; Biomaterials; Bioprinting; 2.5 Conclusion; References; Chapter 3: Clinical Safety and Applications of Stem Cell Gene Therapy; 3.1 Introduction; 3.2 Applications; 3.3 Safety; 3.3.1 Proof of Concept; 3.3.2 The Preclinical Testing Program; 3.3.3 Suicide Genes; 3.4 Efficacy; 3.4.1 Promoter Selection; 3.4.2 Transduction Efficiency; 3.4.3 Engraftment Efficiency; 3.5 Gene Therapy Procedures; 3.6 Way Forward; 3.7 Conclusion; References.